Why the study?
Patients with TIA and minor ischemic stroke face early recurrent ischemia, but anticoagulants increase hemorrhagic transformation, and the safety of dabigatran in acute stroke was unevaluated.
Does dabigatran increase the risk of symptomatic hemorrhagic transformation compared to aspirin in patients with acute minor noncardioembolic ischemic stroke or TIA?
Does dabigatran increase the risk of symptomatic hemorrhagic transformation compared to aspirin in patients with acute minor noncardioembolic ischemic stroke or TIA?
In patients with acute minor noncardioembolic ischemic stroke or TIA, dabigatran demonstrated a similar safety profile to aspirin regarding symptomatic hemorrhagic transformation.
No takes yet. Share an insight, caveat, or question.
Dabigatran shows no increase in symptomatic HT versus aspirin; extends RCT safety data for anticoagulation after minor noncardioembolic stroke or TIA.
Butcher et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: